Antibody drug conjugates (ADCs) are an important class of therapeutic molecule currently being used to treat HER2-positive metastatic breast cancer, relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B-cell precursor acute lymphoblastic leukemia and acute myeloid leukemia. An ADC typically consists of a small molecule or peptide-based cytotoxic moiety covalently linked, via lysine or cysteine residues, to amonoclonal antibody (mAb) scaffold. Mass spectrometric (MS) characterization of thesemolecules afford highly accurate molecular weight (MW) and drug-to-antibody ratio (DAR) determination, and is typically performed using orthogonal acceleration time-of-flight (oa-ToF) analysers and more recently Orbitrap instruments. Herein we describe for the first time the use of a 15 Tesla solariX Fourier transform ion cyclotron mass spectrometer to characterize an IgG1 mAb molecule conjugated with biotin via native lysine and cysteine residues, under native-MS and solution conditions. The cysteine biotin conjugates remained fully intact, demonstrating the ability of the FT-ICR to maintain the noncovalent interactions and efficiently transmit labile protein complexes. Native-MS was acquired and is displayed in magnitude mode using a symmetric Hann apodisation function. Baseline separation is achieved on all covalent biotin additions, for each charge state, for both the lysine and cysteine biotin-conjugates. Average DAR values obtained by native-MS for the lysine conjugate are compared to those derived by denaturing reversed phase liquid chromatography using an oa-ToF MS system (1.56 ±0.02
Introduction
In recent years, antibody-drug conjugates (ADCs) have emerged as a promising class of protein therapeutics based on chemical conjugation technologies 1 . ADCs are designed for highly targeted delivery of a potent cytotoxic molecule to the tumour cell with minimal systemic toxicity 2 .
Currently four ADCs, ado-Trastuzumab emtansine (Kadcyla;
Genentech/Immunogen), Brentuximab vedotin (Adcetris; Seattle Genetics), Inotuzumab ozogamicin (Besponsa; Pfizer) and Gemtuzumab ozogamicin (Gemtuzumaba; Pfizer) have been approved by the US FDA. Moreover, there are more than 20 ADCs in various stages of clinical trials 3, 4 . The current technology utilises lysine and cysteine modification of antibodies, in which the drug is conjugated to the antibody using a linker [5] [6] [7] [8] . Lysine conjugation typically results in a distribution of drug-to-antibody ratio (DAR) ranging from 0 to 8 5, 9 . Cysteine conjugation can take place through covalent modification of an engineered cysteine residue 10 or a reduced interchain disulphide bond(s) 11 resulting in a DAR distribution incrementally increasing by two units (DAR= 0, 2, 4, 6 and 8) 11, 12 .
Analysis of proteins and macromolecular complexes under native-MS and solution conditions
has predominantly focused on gas-phase structural biology [13] [14] [15] where native stoichiometry can be readily determined. However more recently, the combination of ion mobility and MS can provide additional shape information, in the form of an ion-neutral collision cross section value 16 , where large levels of gas-phase collapse have been characterized for mAbs 17, 18 . Advances in instrument design have further showcased MS analysis of mAbs 19, 20 , both native and denatured, using the Orbitrap analyser. Native-MS analysis of ADCs has been increasing over the past decade for a number of reasons, chief of which are that MS can provide highly accurate DAR values specifically determined under native-MS and solution conditions, critical for cysteine conjugates 11, 21, 22 . The FT-based Orbitrap instrument, typically the extended mass range Orbitrap 19, 23 have been readily adopted in both industry and academia for the analysis of mAbs 19, 24 and ADCs 24,25 under native-MS and solution conditions due to the Orbitraps exemplary data quality over that typically achieved on oa-ToF instruments 18, 19, 25 and now high mass transmission capabilities 19, 23, 24, 26 . Over the past 5 years a number of groups have used Fourier transform ion cyclotron resonance (FT-ICR) instrumentation to analyse mAbs under native 27 and denaturing 28, 29 conditions. However, to our knowledge, ADCs have not yet been analysed using an FT-ICR, let alone under native-MS and solution conditions.
The purpose of this short communication is not to be an exhaustive ADC native-MS comparison between multiple instrument platforms (FT-ICR versus oa-ToF versus Orbitrap). But instead a demonstration of the capabilities of the 15 Tesla solariX FT-ICR to analyse a human IgG1 mAb conjugated with biotin, via native lysine and cysteine residues, as representative ADCs, analysed under native-MS and solution conditions. Native-MS derived DAR values are calculated and compared to those determined by the industry standard analytical method, denaturing LC-MS 30 .
Finally we demonstrate reliable deconvolution of both denatured and native-MS spectra using a parsimonious model-based deconvolution algorithm 31 .
Materials and Methods

Biotinylation of mAbs on lysine and cysteine residues
Briefly, for lysine conjugation (Scheme 1a) a human IgG1mAb standard was alkylated with 5 or 10-equivalents of EZ-Link sulfo-NHS-LC-biotin (Peirce). For cysteine conjugation (Scheme 1b) the mAb was partially reduced with 5 or 10-equivalents of tris(2-carboxyethyl)phosphine (TCEP) for 90 min at RT and then alkylated with 10-equivalents of EZ-Link iodoacetyl-LCbiotin (Pierce). This bespoke mAb conjugate was chosen over a commercial ADC, since the lysine and cysteine conjugation described herein, was easily performed on the same IgG construct to varying levels not observed in a commercial molecule. A more detailed explanation of the alkylation reaction can be found in the Supporting Information. Table 1 ). The observed MWs correspond to the expected mass additions of 339.5
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Da (lysine conjugation) and 383.5 Da (cysteine conjugation). Importantly, well separated ADC species for each charge state are also observed and achieved using very mild activation voltages (source skimmer 50 V; collision cell 20 V). The glycosylated 5 and 10-molar biotin equivalents of the lysine conjugated molecules are displayed in the Supporting Information ( Figure S1) where peak separation is achieved between the covalent biotin adduct (lysine) and the different glycoforms (G0F, G1F, G2F). In all aforementioned cases the observed charge state distributions are consistent with those previously observed for native-MS analyses of mAbs 19, 27 and ADCs 11, 25 and importantly are consistent with the expected charge state distribution described by de la Mora 34 based on the power relationship z = 0.0778 Mw 0.5 . Figure 1a , Inset I, displays baseline separated charges states (z = 30+ to 26+) and differing DAR values (0 to 5) for the deglyycosylated lysine modified mAb with 5-equivalents of biotin. The overall DAR value, accounting for all observable charge states is 1.56 ±0.02 (Table 1) and was calculated from a zero-charge deconvoluted spectrum (Figure 1a , Inset II). Also detected ( Figure   1a , Inset I) is low level (5%) glycation 35 This is a lower DAR value than that obtained from the denatured LC- Under the aforementioned denaturing LC-MS conditions, protein gas-phase [39] [40] [41] and solution 42 conformations are more extended and unfolded, the effect of which is most dramatic for the lowest DAR value species (vide infra). This increased level of unfolding results in improved detection efficiencies most likely due to the improved signal-to-noise ratio that is typically observed higher for denaturing spectra. One must also consider the increased levels of ADC adducting when the ADC is in a folded state. Under native-MS and solution conditions, protein adducting from sodium for example, can reduce overall molecular ion abundances 43, 44 , the results of which are particularly acute for the low level species (DARs 5 & 6). Chen 45 has also postulated increased hydrophobicity levels for higher drug load molecules, resulting in reduced ionization efficiencies. Also observed by multiple groups are significant differences in calculated DAR values obtained using different analytical techniques, such as hydrophobic interaction chromatography versus native-MS 45 and native-IM-MS 25 .
The DAR values calculated for the denatured mAb will also be inherently more accurate and consistent, since a higher number of charge states are being selected for deconvolution ( Figure   S2 & S3, Supporting Information). Additionally, the ESI process is significantly aided by the pneumatic nebulization and desolvation which is heated and operated at a significantly higher flow rate, reducing ion current fluctuations. These variations are potentially exacerbated when analysing under nESI conditions. As a result, more accurate DAR values can be obtained with lower SD values (Table 1) when using standard ESI conditions as opposed to nESI native-MS conditions.
Conclusion
The This is important, since charge states are generally more adducted under native-MS conditions and previous Maximum Entropy based algorithms 37 have struggled to deconvolute native MSspectra with these increased levels of added complexity 46 A limited number of high mass applications have been demonstrated by FT-ICR analysis 47, 48 .
However, over the past 5 years more native gas-phase protein and high mass applications have been described by FT-ICR where the applications have ranged from mAbs 27 , to membrane proteins 49, 50 , nanodiscs 49, 51, 52 and native protein top-down analyses 53, 54 . The native-MS data presented herein further demonstrates the enabling capabilities of an unmodified FT-ICR platform for native high mass (and high m/z) analysis, producing mAb conjugate data equivalent in quality to that previously only thought to be achievable using oa-ToF analysers [55] [56] [57] [58] [59] and more recently the Orbitrap 19, 23, 26, 60 . The user has the ability to acquire data at ultrahigh resolution.
One can also perform ECD 53 
